Seoul Economic Daily EnglishCodex · 实盘不做把握 6/10
北京时间·🕒 发布 09:07:25时区推断·⟳ 抓取 09:25:39·⚡ 决策 07-28 09:28:20 +2m41s·91.4 天前
AriBio完成AR1001阿尔茨海默病III期试验末例随访，年内才披露顶线数据
本次只是LPLV/试验流程完成，未披露疗效或安全性顶线数据，真正会改变AR1001价值的读数仍在年内后续公布。
📄 原文Seoul Economic Daily English↗ 原文
AriBio Completes Global Phase 3 Trial of Oral Alzheimer's Drug, Topline Results Due This Year
AriBio has officially concluded the global Phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease.…
不做 复星医药（600196.SH）
本次只是AR1001 III期末例末访完成，未披露顶线疗效/安全性数据；复星行权和商业化价值仍取决于后续读数，当前不做。
不做 复星医药（02196.HK）
同一公司H股承接的也是AR1001选择权期权价值，但当前流程节点缺少可交易的临床成功增量，且5月选择权和年内读数预期已公开，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 复星医药与AriBio已公告AR1001全球独家选择权，并说明顶线结果预计2026年公布、复星在取得顶线数据后决定是否行权。
- 已报道AR1001主研究52周给药完成，说明本次7月LPLV属于同一临床进度的后续流程节点。
- 报道AriBio完成全球III期LPLV，并将在数据清理、锁库和统计分析后披露顶线结果。
- 本信号源报道同一LPLV完成事项，距抓取约18分钟，但信息本身不是疗效读数。
关键理由
- 本次只是LPLV/试验流程完成，未披露疗效或安全性顶线数据，真正会改变AR1001价值的读数仍在年内后续公布。
- 复星医药此前已在5月公告AR1001全球独家选择权，顶线数据后90天内才决定是否行权，当前事件对短期收入利润没有新增可量化贡献。
- AR1001若成功有期权价值，但现阶段只能说明临床按计划推进，不能替代临床成功信号。
主要风险
- 若后续顶线数据显著阳性，复星医药的选择权价值会重新定价；当前不做的核心风险是错过数据前博弈。
- 阿尔茨海默病III期读数二元风险高，未出数据前不宜把流程里程碑当成确定性利好。
原文全文
展开原文 · 2,190 字
AriBio has officially concluded the global Phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease. The company plans to announce the topline results of the Phase 3 trial this year, following data verification and analysis.
AriBio said on the 28th that it had completed the "last patient, last visit" (LPLV) in its Phase 3 trial spanning 13 countries. LPLV marks the point at which the last dosed patient completes final adverse event and safety assessments.
AriBio has been conducting the Phase 3 trial in about 230 clinical institutions across 13 countries, including the United States, Europe, Korea, and China, enrolling 1,535 patients with early-stage Alzheimer's disease. Last month, the trial completed 52 weeks of dosing for main-study patients. The last dosed patient also completed the final safety follow-up visit, conducted four weeks later, as scheduled on the 27th of this month.
Accordingly, AriBio is now cleaning data collected from clinical institutions worldwide. After reviewing data queries, key evaluation variables, and safety information, the company plans to proceed with database lock and statistical analysis.
AriBio will first release the topline results as soon as the 52-week efficacy and safety findings for AR1001 are derived. It plans to officially present detailed clinical results at the opening session of "CTAD 2026," the Clinical Trials on Alzheimer's Disease conference, to be held in Boston, United States, this November.
"We completed the large-scale Phase 3 trial conducted in 13 countries as planned," said Jung Jae-jun, CEO of AriBio. "By prioritizing the completeness of the data and the accuracy of the analysis, we will focus our company-wide capabilities on data lock and statistical analysis to clearly present the clinical value of AR1001."
Meanwhile, 95.5% of eligible patients enrolled in the long-term extension trial that follows the 52-week main study, with more than 1,250 currently receiving dosing and evaluation. The trial is scheduled to end in July next year. The company plans to use up to two years of long-term safety and efficacy data as key material to enhance treatment reliability in clinical settings.
AriBio said on the 28th that it had completed the "last patient, last visit" (LPLV) in its Phase 3 trial spanning 13 countries. LPLV marks the point at which the last dosed patient completes final adverse event and safety assessments.
AriBio has been conducting the Phase 3 trial in about 230 clinical institutions across 13 countries, including the United States, Europe, Korea, and China, enrolling 1,535 patients with early-stage Alzheimer's disease. Last month, the trial completed 52 weeks of dosing for main-study patients. The last dosed patient also completed the final safety follow-up visit, conducted four weeks later, as scheduled on the 27th of this month.
Accordingly, AriBio is now cleaning data collected from clinical institutions worldwide. After reviewing data queries, key evaluation variables, and safety information, the company plans to proceed with database lock and statistical analysis.
AriBio will first release the topline results as soon as the 52-week efficacy and safety findings for AR1001 are derived. It plans to officially present detailed clinical results at the opening session of "CTAD 2026," the Clinical Trials on Alzheimer's Disease conference, to be held in Boston, United States, this November.
"We completed the large-scale Phase 3 trial conducted in 13 countries as planned," said Jung Jae-jun, CEO of AriBio. "By prioritizing the completeness of the data and the accuracy of the analysis, we will focus our company-wide capabilities on data lock and statistical analysis to clearly present the clinical value of AR1001."
Meanwhile, 95.5% of eligible patients enrolled in the long-term extension trial that follows the 52-week main study, with more than 1,250 currently receiving dosing and evaluation. The trial is scheduled to end in July next year. The company plans to use up to two years of long-term safety and efficacy data as key material to enhance treatment reliability in clinical settings.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。